N-[1-(acetylthiomethyl)cyclopentane-carbonyl]-(S)-methionine ethyl ester | 137613-73-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[1-(acetylthiomethyl)cyclopentane-carbonyl]-(S)-methionine ethyl ester
• 英文别名: N-[1-(acetylthiomethyl)cyclopentanecarbonyl]-(S)-methionine ethyl ester；ethyl (2S)-2-[[1-(acetylsulfanylmethyl)cyclopentanecarbonyl]amino]-4-methylsulfanylbutanoate
• CAS: 137613-73-1
• 化学式: C₁₆H₂₇NO₄S₂
• 分子量: 361.527
• InChiKey: WYPJYXKWBXYEBI-ZDUSSCGKSA-N

物化性质

• 沸点：
  535.2±40.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  123
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[1-(acetylthiomethyl)cyclopentane-carbonyl]-(S)-methionine ethyl ester 在 盐酸 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 N-[1-(MERCAPTOMETHYL)CYCLOPENTANECARBONYL]-(S)-METHIONINE
  参考文献：
  名称：

  Mercaptocycloacyl aminoacid endopeptidase inhibitors

  摘要：

  公开了公式##STR1##的内肽酶巯基环酰氨基酸抑制剂或其药学上可接受的盐，单独或与ACE抑制剂或ANF结合，用于治疗高血压、充血性心力衰竭、水肿和肾功能不全等心血管疾病，以及治疗肾毒性疼痛症状，并且公开了含有这些化合物的药物组合物。

  公开号：

  US05407960A1
• 作为产物：
  描述：

  tert-butyl cyclopentanecarboxylate 在 N-甲基吗啉 、 正丁基锂 、 dipyridyl 、 potassium carbonate 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 二异丙胺 、 三氟乙酸 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 78.5h， 生成 N-[1-(acetylthiomethyl)cyclopentane-carbonyl]-(S)-methionine ethyl ester
  参考文献：
  名称：

  Mercaptoacyl aminoacid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivatives

  摘要：

  A broad series of N-(3-mercaptoacyl) amino acid derivatives was evaluated for their ability to inhibit atriopeptidase (neutral endopeptidase, EC 3.4.24.11) in vitro and in vivo. Structural parameters studied were (i) the substituent on the 2-position of the 3-mercaptopropionyl moiety, (ii) the amino acid component, (iii) the S-terminal derivative, and (iv) the C-terminal derivative. Optimum activity was observed for derivatives of methionine and S-alkylcysteines. N-[3-Mercapto-2(S)-[(2-methylphenyl)methyl]-1-oxopropyl]-L-methionine was identified as a highly effective inhibitor of atriopeptidase meriting evaluation as a potential cardiovascular therapeutic agent.

  DOI：

  10.1021/jm00041a026

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：INTRA CELLULAR THERAPIES INC

  公开号：WO2016022893A1

  公开（公告）日：2016-02-11

  The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

  该发明涉及新型磷酸二酯酶1（PDE1）抑制剂，用于治疗由于某些cGMP/PKG介导的途径受到破坏或损害而表现出的疾病或紊乱（例如在心脏组织中）。该发明还涉及包含该抑制剂的药物组合物以及治疗心血管疾病和相关疾病的方法，例如充血性心力衰竭、动脉粥样硬化、心肌梗死和中风。
• ORGANIC COMPOUNDS
  申请人：Intra-Cellular Therapies, Inc.

  公开号：US20160039829A1

  公开（公告）日：2016-02-11

  The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

  本发明涉及新型磷酸二酯酶1（PDE1）抑制剂，用于治疗由于某些cGMP/PKG介导的通路（例如在心脏组织中）受到破坏或损伤而表现出的疾病或障碍。本发明还涉及包含该抑制剂的制药组合物以及用于治疗心血管疾病和相关疾病的方法，例如充血性心脏病，动脉粥样硬化，心肌梗死和中风。
• COMPOUNDS CONTAINING S-N-VALERYL-N--VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS
  申请人：Feng Lili

  公开号：US20160324821A1

  公开（公告）日：2016-11-10

  A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.

  一种治疗心血管或肾脏疾病的方法，使用特定组合、联接型前药或血管紧张素受体拮抗剂和NEPi化合物。
• Stabilized polymeric dispersions
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP0413551A2

  公开（公告）日：1991-02-20

  Stable latices of polymer particles insoluble in non-polar organic solvents are prepared by the attachment of the insoluble polymer particles to a stabilizer soluble in the non-polar organic solvent. The stabilizer comprises the adduct of a polymer bearing pendant azlactone groups which is soluble in non-polar organic solvents and an ethylenically unsaturated nucleophile bearing an azlactone reactive nucleophilic moiety.

  通过将不溶于非极性有机溶剂的聚合物颗粒附着到可溶于非极性有机溶剂的稳定剂上，制备出不溶于非极性有机溶剂的聚合物颗粒的稳定乳胶。稳定剂包括可溶于非极性有机溶剂的、带有唑内酯基团的聚合物与带有唑内酯活性亲核分子的乙烯不饱和亲核剂的加合物。
• Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
  申请人：SCHERING CORPORATION

  公开号：EP0509442A1

  公开（公告）日：1992-10-21

  Treatment and prevention of immunosuppression therapy-induced nephrotoxicity with neutral endopeptidases such as N-[N-[(L)-[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)-methoxy]carbonyl]-2-phenylethyl]-L-phenylalanyl]-β-alanine and N-[2-mercaptomethyl-3-(2-methylphenyl)propioyl]-methionine are disclosed.

  本研究公开了用中性内肽酶（如 N-[N-[(L)-[1-[(2,2-二甲基-1,3-二氧戊环-4-基)-甲氧基]羰基]-2-苯基乙基]-L-苯基丙氨酰]-β-丙氨酸和 N-[2-巯甲基-3-(2-甲基苯基)丙酰]-甲硫氨酸）治疗和预防免疫抑制疗法引起的肾毒性。